Revenue GrowthStrong revenue growth indicates robust market demand and successful product adoption, which can lead to increased market share and long-term business sustainability.

Low LeverageMinimal leverage reduces financial risk and enhances the company's ability to invest in growth opportunities without the burden of high interest obligations.

Free Cash Flow AlignmentPositive alignment between free cash flow and net income suggests efficient cash management, supporting sustainable operations and potential reinvestment in the business.

Bears Say

Negative MarginsNegative margins indicate cost management issues and operational inefficiencies, which can hinder profitability and long-term financial health.

Cash Flow ChallengesPersistent cash flow challenges can constrain the company's ability to fund operations and growth initiatives, potentially impacting future performance.

Negative Return On EquityNegative return on equity reflects poor returns for shareholders, indicating inefficiencies in utilizing equity capital to generate profits.

IVACC FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was kr0.75 and its highest was kr1.35 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is kr295.83M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is Feb 17, 2026 which is tomorrow.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Nov 19, 2025. The company reported -kr0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.04.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is -0.06.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -kr0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.064%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in SE:IVACC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.